2m 2m 2m 2m 2m 2m 2m
APIMEDS PHARM (APUS)
NYSE
$0.73-$0.003 (-0.41%)
Price as of Jul 13, 2026 7:47 PM EDT- $10.9MMarket Cap
- -95.99%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
APIMEDS PHARM (APUS)
$0.73-$0.003 (-0.41%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The Schall Law Firm is investigating Apimeds Pharmaceuticals US, Inc. (APUS), Elite Express Holding Inc. (ETS), and Decent Holding Inc. (DXST) for potential securities law violations, including allegations of false statements and failure to disclose material information to investors. Affected shareholders are encouraged to participate in the investigation.
04/26/2026, 8:12 PM • GlobeNewswire
Peers
Statistics
MoreDay Range
$0.71
$0.74
$0.74
1-Year Range
$0.72
$3.90
$0.74
Latest Close$0.74
Change
+$0.02 (+2.31%)
Volume63,431
Market Cap$10.9M
Shares Outstanding15.1M
P/E (TTM)-0.23
Diluted EPS (TTM)-$3.18
Enterprise Value$18.1M
Information as of 07/13/2026
Company Profile
APIMEDS PHARMACEUTICALS US INC
https://www.mindwavedao.com$10.9M
Market Cap
-$40.7M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
100 Matawan Rd, Matawan, NJ, United States, 07747
848 201 5010Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Key Executives
- Erik C. Emerson
- Christopher Kim
- Erick J. Frim
- Sungjoon Chae
- Captain Sandeep Yadav
Current Ownership Distribution
- Institutions448,756 (35.68%)
- Mutual Funds315,813 (25.11%)
- Insiders268,000 (21.31%)
- Other225,029 (17.89%)